Patents by Inventor Bruce L. Geller
Bruce L. Geller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220135973Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: ApplicationFiled: October 12, 2021Publication date: May 5, 2022Applicants: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David GREENBERG, Bruce L. GELLER
-
Patent number: 11293024Abstract: Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combination with other antimicrobial agents, for instance, in the treatment of an infected mammalian subject.Type: GrantFiled: December 23, 2015Date of Patent: April 5, 2022Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: Bruce L. Geller, David Greenberg
-
Patent number: 11142764Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: GrantFiled: December 22, 2016Date of Patent: October 12, 2021Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David Greenberg, Bruce L. Geller
-
Patent number: 11021706Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: GrantFiled: September 1, 2017Date of Patent: June 1, 2021Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: Bruce L. Geller, David Greenberg
-
Publication number: 20210155934Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: ApplicationFiled: February 1, 2021Publication date: May 27, 2021Applicants: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David GREENBERG, Bruce L. GELLER, Erdal TOPRAK
-
Patent number: 10907158Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: GrantFiled: December 22, 2016Date of Patent: February 2, 2021Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David Greenberg, Bruce L. Geller, Erdal Toprak
-
Publication number: 20200283768Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: ApplicationFiled: October 19, 2018Publication date: September 10, 2020Applicants: Board of Regents, The University of Texas System, Oregon State UniversityInventors: Bruce L. GELLER, David GREENBERG
-
Publication number: 20200032254Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: ApplicationFiled: September 1, 2017Publication date: January 30, 2020Inventors: Bruce L. Geller, David Greenberg
-
Patent number: 10391098Abstract: Provided are antisense oligomers targeted against or genes associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: GrantFiled: May 15, 2015Date of Patent: August 27, 2019Assignees: Board of Regents, The University of Texas System, Oregon State UniversityInventors: Bruce L. Geller, David Greenberg
-
Publication number: 20190169609Abstract: Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combination with other antimicrobial agents, for instance, in the treatment of an infected mammalian subject.Type: ApplicationFiled: December 23, 2015Publication date: June 6, 2019Inventors: Bruce L. Geller, David Greenberg
-
Publication number: 20190078095Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or essential genes, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: ApplicationFiled: December 22, 2016Publication date: March 14, 2019Applicants: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David GREENBERG, Bruce L. GELLER, Erdal TOPRAK
-
Publication number: 20180362982Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: ApplicationFiled: December 22, 2016Publication date: December 20, 2018Applicants: Board of Regents, The University of Texas System, Oregon State UniversityInventors: David GREENBERG, Bruce L. GELLER
-
Patent number: 10144762Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.Type: GrantFiled: October 14, 2016Date of Patent: December 4, 2018Assignee: SAREPTA THERAPEUTICS, INC.Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
-
Patent number: 9790495Abstract: Provided are antisense morpholino oligomers targeted against bacterial virulence factors such as genes that contribute to antibiotic resistance or biofilm formation, or genes associated with fatty acid biosynthesis, and related compositions and methods of using the oligomers and compositions, for instance, in the treatment of an infected mammalian subject.Type: GrantFiled: May 15, 2015Date of Patent: October 17, 2017Assignees: Oregon State University, Board of Regents, The University of Texas SystemInventors: Bruce L. Geller, David Greenberg
-
Publication number: 20170247410Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.Type: ApplicationFiled: October 14, 2016Publication date: August 31, 2017Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
-
Patent number: 9534220Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.Type: GrantFiled: November 19, 2012Date of Patent: January 3, 2017Assignee: Sarepta Therapeutics, Inc.Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
-
Patent number: 9499583Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.Type: GrantFiled: December 21, 2015Date of Patent: November 22, 2016Assignee: Sarepta Therapeutics, Inc.Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
-
Patent number: 9487784Abstract: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a Tm of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.Type: GrantFiled: November 19, 2012Date of Patent: November 8, 2016Assignee: Sarepta Therapeutics, Inc.Inventors: Bruce L. Geller, Jesse D. Deere, Patrick L. Iversen
-
Publication number: 20160251398Abstract: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3? or 5? end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.Type: ApplicationFiled: December 21, 2015Publication date: September 1, 2016Inventors: Dwight D. Weller, Bruce L. Geller, Patrick L. Iversen, Lucas D. Tilley, Jed N. Hassinger
-
Publication number: 20160106857Abstract: Provided are antisense oligomers targeted against or genes associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.Type: ApplicationFiled: May 15, 2015Publication date: April 21, 2016Inventors: Bruce L. Geller, David Greenberg